Moderate-to-severe ovarian hyperstimulation syndrome: A retrospective multivariate logistic regression analysis in Chinese patients

被引:7
作者
Ma, Tianzhong [1 ]
Niu, Yanru [1 ]
Wei, Bing [1 ]
Xu, Lihua [1 ]
Zou, Lin [1 ]
Che, Xiaoqun [1 ]
Wang, Xiao [1 ]
Tang, Di [1 ]
Huang, Riyan [1 ]
Chen, Bi [1 ]
机构
[1] Guangdong Med Univ, Reprod Med Ctr, Affiliated Hosp, Zhanjiang, Peoples R China
来源
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE | 2020年 / 29卷 / 01期
关键词
in vitro fertilization; ovarian hyperstimulation syndrome; human chorionic gonadotropin; SYNDROME PATHOPHYSIOLOGY; SYNDROME OHSS; DOUBLE-BLIND; PREDICTION; PREVENTION;
D O I
10.17219/acem/92916
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background. Ovarian hyperstimulation syndrome (OHSS), a life-threatening complication occurring in stimulated ovarian cycles, arises from treatment with gonadotropin for inducing follicular maturation. Objectives. The aim of this study was to compare the risk factors between patients with severe OHSS and those without OHSS after in vitro fertilization by intracytoplasmatic sperm injection/embryo transfer (IVF-ICSI/ET). Identifying the associated risk factors may provide guidance for clinicians on how to prevent OHSS. Material and methods. The retrospective study involved patients who had completed IVF-ICSI/ET cycles. The difference in markers for predicting the occurrence of OHSS between groups was compared. The potential protective and risk factors, as well as the predictive markers, were identified. Results. Patients with OHSS were younger (p = 0.015), had higher basal antral follicle counts (AFC) (p < 0.001) and lower total dosages of gonadotropin (Gn) (p = 0.011). On the day of human chorionic gonadotropin (hCG) administration, significantly higher total numbers of follicles (p < 0.001), serum estradiol (E2) (p < 0.001) and progestrone (Pg) (p = 0.001) levels, numbers of oocytes (p < 0.001) and metaphase II (MII) oocytes (p < 0.001) were also observed in the OHSS group when compared to the non-OHSS group. A univariate regression analysis revealed that age (OR = 0.898, 95% CI =0.822-0.981) and total dosage of Gn (OR = 0.999, 95% CI = 0.999-1.000) were protective factors, whereas AFC (OR = 1.090, 95% CI = 1.051-1.131) and, on the day of hCG injection, the number of follicles (OR = 1.185, 95% CI = 1.027-1.230), serum E2 (OR = 1.000, 95% CI = 1.000-1.000) and Pg (OR = 2.773, 95% CI = 0.510-3.370) levels, the number of oocytes (OR = 1.254, 95% CI = 0.894-1.472) and MII oocytes (OR = 1.238, 95% CI = 0.747-1.217) were risk factors for OHSS. However, a multivariate regression analysis showed that the total number of follicles (OR = 1.124, 95% CI = 1.027-1.230) was the only predictive factor for the occurrence of OHSS. Conclusions. The study demonstrated that the follicle count measured on the day of hCG administration was the only predictive factor forthe occurrence of OHSS. This provides basic guidance to clinicians on the prevention of the complication when using assisted reproductive technologies (ART).
引用
收藏
页码:85 / 90
页数:6
相关论文
共 21 条
[1]   Prediction of ovarian hyperstimulation syndrome (OHSS) - Estradiol level has an important role in the prediction of OHSS [J].
Aboulghar, M .
HUMAN REPRODUCTION, 2003, 18 (06) :1140-1141
[2]   Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures [J].
Aboulghar, MA ;
Mansour, RT .
HUMAN REPRODUCTION UPDATE, 2003, 9 (03) :275-289
[3]  
[Anonymous], 2013, HUM REPROD S1, V28, P370
[4]   Risk factors for ovarian hyperstimulation syndrome in Thai patients using gonadotropins for in vitro fertilization [J].
Aramwit, Pornanong ;
Pruksananonda, Kamthorn ;
Kasettratat, Narat ;
Jammeechai, Karnphat .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (12) :1148-1153
[5]   The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial† [J].
Busso, Cristiano ;
Fernandez-Sanchez, Manuel ;
Antonio Garcia-Velasco, Juan ;
Landeras, Jose ;
Ballesteros, Augustin ;
Munoz, Elkin ;
Gonzalez, Sandra ;
Simon, Carlos ;
Arce, Joan-Carles ;
Pellicer, Antonio .
HUMAN REPRODUCTION, 2010, 25 (04) :995-1004
[6]   Assisted reproductive technology in Europe, 2006: results generated from European registers by ESHRE [J].
de Mouzon, J. ;
Goossens, V. ;
Bhattacharya, S. ;
Castilla, J. A. ;
Ferraretti, A. P. ;
Korsak, V. ;
Kupka, M. ;
Nygren, K. G. ;
Andersen, A. Nyboe .
HUMAN REPRODUCTION, 2010, 25 (08) :1851-1862
[7]   Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review [J].
Delvigne, A ;
Rozenberg, S .
HUMAN REPRODUCTION UPDATE, 2002, 8 (06) :559-577
[8]  
Golan A, 1989, Obstet Gynecol Surv, V44, P430, DOI 10.1097/00006254-198906000-00004
[9]   Preventing ovarian hyperstimulation syndrome: guidance for the clinician [J].
Humaidan, Peter ;
Quartarolo, Jens ;
Papanikolaou, Evangelos G. .
FERTILITY AND STERILITY, 2010, 94 (02) :389-400
[10]   The pathogenesis of the ovarian hyperstimulation syndrome [J].
Kaiser, UB .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (08) :729-732